The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
For recipient of the ESMO Lifetime Achievement Award, Prof. John Haanen, melanoma research has provided him with a career full of innovation, but there is always more to explore
According to Prof. Serena Nik-Zainal, 2024 ESMO Translational Research Awardee it is important to change the mindset of the cancer community to embrace all the information available through genome research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.